EP1519747A4 - Human monoclonal antibodies to prostate specific membrane antigen (psma) - Google Patents

Human monoclonal antibodies to prostate specific membrane antigen (psma)

Info

Publication number
EP1519747A4
EP1519747A4 EP03721280A EP03721280A EP1519747A4 EP 1519747 A4 EP1519747 A4 EP 1519747A4 EP 03721280 A EP03721280 A EP 03721280A EP 03721280 A EP03721280 A EP 03721280A EP 1519747 A4 EP1519747 A4 EP 1519747A4
Authority
EP
European Patent Office
Prior art keywords
psma
monoclonal antibodies
human monoclonal
prostate specific
specific membrane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03721280A
Other languages
German (de)
French (fr)
Other versions
EP1519747A2 (en
Inventor
Yashwant M Deo
Robert Graziano
Debra Hudson
Eric H Holmes
William T Tino
Amelia Black
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ER Squibb and Sons LLC
Original Assignee
Medarex LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medarex LLC filed Critical Medarex LLC
Publication of EP1519747A2 publication Critical patent/EP1519747A2/en
Publication of EP1519747A4 publication Critical patent/EP1519747A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP03721280A 2002-01-28 2003-01-28 Human monoclonal antibodies to prostate specific membrane antigen (psma) Withdrawn EP1519747A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5998902A 2002-01-28 2002-01-28
US59989 2002-01-28
PCT/US2003/002448 WO2003064606A2 (en) 2002-01-28 2003-01-28 Human monoclonal antibodies to prostate specific membrane antigen (psma)

Publications (2)

Publication Number Publication Date
EP1519747A2 EP1519747A2 (en) 2005-04-06
EP1519747A4 true EP1519747A4 (en) 2006-03-29

Family

ID=27658271

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03721280A Withdrawn EP1519747A4 (en) 2002-01-28 2003-01-28 Human monoclonal antibodies to prostate specific membrane antigen (psma)

Country Status (10)

Country Link
EP (1) EP1519747A4 (en)
JP (1) JP2005518789A (en)
KR (1) KR20040077889A (en)
CN (1) CN1652821A (en)
AU (1) AU2003224604B2 (en)
BR (1) BR0307216A (en)
CA (1) CA2474616A1 (en)
MX (1) MXPA04007262A (en)
NZ (1) NZ534687A (en)
WO (1) WO2003064606A2 (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105159B1 (en) 1992-11-05 2006-09-12 Sloan-Kettering Institute For Cancer Research Antibodies to prostate-specific membrane antigen
US6569432B1 (en) 1995-02-24 2003-05-27 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof
US6962981B1 (en) 1996-03-25 2005-11-08 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US7381407B1 (en) 1996-03-25 2008-06-03 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
AU2002356844C1 (en) 2001-10-23 2010-03-04 Amgen Fremont Inc. PSMA antibodies and protein multimers
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
PL1691837T3 (en) * 2003-12-10 2012-11-30 Squibb & Sons Llc Ip-10 antibodies and their uses
ES2533492T3 (en) * 2004-02-06 2015-04-10 University Of Massachusetts Antibodies against Clostridium difficile toxins and their uses
ES2387809T3 (en) * 2004-03-19 2012-10-02 Imclone Llc Antibody to human epidermal growth factor receptor
CA2885854C (en) 2004-04-13 2017-02-21 F. Hoffmann-La Roche Ag Anti-p-selectin antibodies
PL2287195T3 (en) 2004-07-01 2019-10-31 Novo Nordisk As Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy
CN104829720B (en) 2005-01-06 2019-01-01 诺和诺德公司 KIR bonding agent and the method for using it
AU2006214031A1 (en) * 2005-02-18 2006-08-24 Medarex, Inc. Human monoclonal antibodies to prostate specific membrane antigen (PSMA)
MX2007009935A (en) * 2005-02-18 2007-10-10 Medarex Inc Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues.
LT2439273T (en) * 2005-05-09 2019-05-10 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
EP1726650A1 (en) * 2005-05-27 2006-11-29 Universitätsklinikum Freiburg Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
US7696185B2 (en) * 2006-03-14 2010-04-13 Cancer Targered Technology LLC Peptidomimetic inhibitors of PSMA, compounds comprising them, and methods of use
US8852630B2 (en) 2008-05-13 2014-10-07 Yale University Chimeric small molecules for the recruitment of antibodies to cancer cells
EP2727606A3 (en) 2008-09-08 2015-09-23 Psma Development Company, L.L.C. Compounds for killing psma-expressing, taxane-resistant cancer cells
DK2356153T3 (en) * 2008-10-01 2016-07-04 Amgen Res (Munich) Gmbh Bispecific single CHAIN ​​PSMAXCD3 ANTIBODY THAT ARE SPECIFICALLY TO ALL SPECIES
CN101891818B (en) * 2009-01-16 2012-07-25 中国人民解放军第四军医大学 Single-chain antibody in anti-human prostate-specific membrane antigen extracellular region and application thereof
WO2010118522A1 (en) * 2009-04-14 2010-10-21 Proscan Rx Pharma Inc. Antibodies against prostate specific membrane antigen
CN103561771B (en) 2011-03-17 2019-01-04 伯明翰大学 The immunization therapy redirected
SG194510A1 (en) 2011-04-22 2013-12-30 Emergent Product Dev Seattle Prostate-specific membrane antigen binding proteins and related compositionsand methods
HUE045435T2 (en) 2012-10-12 2019-12-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CA2905181C (en) 2013-03-13 2020-06-02 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
CN103333249A (en) * 2013-06-14 2013-10-02 广州康合生物科技有限公司 PSMA (Prostate Specific Membrane Antigen) monoclonal antibody and applications thereof
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US10100126B2 (en) * 2015-03-10 2018-10-16 Sorrento Therapeutics, Inc. Antibody therapeutics that bind PSMA
IL293719B2 (en) 2015-05-21 2023-07-01 Harpoon Therapeutics Inc Trispecific binding proteins and methods of use
EP3352760A4 (en) 2015-09-21 2019-03-06 Aptevo Research and Development LLC Cd3 binding polypeptides
KR101704379B1 (en) * 2015-10-27 2017-02-08 (주)알테오젠 Antibody-Drug Conjugate and Method of Producing the Same
AU2017237543B2 (en) * 2016-03-23 2020-02-06 Institut Pasteur Korea Antibody that binds to envelope glycoprotein of severe fever with thrombocytopenia syndrome virus, and use for same
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
US10100106B2 (en) 2016-05-20 2018-10-16 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
AU2017267793B2 (en) 2016-05-20 2024-01-25 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
CN109862919A (en) 2016-10-11 2019-06-07 免疫医疗有限公司 The therapeutic agent that antibody-drug conjugates combined immunization mediates
MX2019006043A (en) 2016-11-23 2019-09-26 Harpoon Therapeutics Inc Prostate specific membrane antigen binding protein.
BR112019010602A2 (en) * 2016-11-23 2019-12-17 Harpoon Therapeutics Inc trispecific psma proteins and methods of use
EP3589662A4 (en) 2017-02-28 2020-12-30 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
JP7209936B2 (en) 2017-05-12 2023-01-23 ハープーン セラピューティクス，インク． MSLN-targeting trispecific proteins and methods of use thereof
KR102376863B1 (en) 2017-05-12 2022-03-21 하푼 테라퓨틱스, 인크. mesothelin binding protein
KR102569133B1 (en) 2017-10-13 2023-08-21 하푼 테라퓨틱스, 인크. Trispecific proteins and methods of use
CR20200195A (en) 2017-10-13 2020-08-14 Harpoon Therapeutics Inc B cell maturation antigen binding proteins
JP2021524449A (en) 2018-05-23 2021-09-13 アーデーセー セラピューティクス ソシエテ アノニム Molecular adjuvant
JP7425049B2 (en) 2018-09-25 2024-01-30 ハープーン セラピューティクス，インク． DLL3 binding protein and method of use
EP3897851A2 (en) 2018-12-17 2021-10-27 Revitope Limited Twin immune cell engager
TW202132353A (en) * 2020-02-18 2021-09-01 大陸商和鉑醫藥（上海）有限責任公司 An isolated antigen psma binding protein and the use thereof
AU2021224851A1 (en) 2020-02-21 2022-09-15 Harpoon Therapeutics, Inc. FLT3 binding proteins and methods of use
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
WO2023088966A1 (en) 2021-11-19 2023-05-25 Adc Therapeutics Sa Anti-psma conjugates

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994029457A2 (en) * 1993-06-09 1994-12-22 Unilever N.V. Process for producing fusion proteins comprising scfv fragments by a transformed mould
WO2001009192A1 (en) * 1999-07-29 2001-02-08 Medarex, Inc. Human monoclonal antibodies to prostate specific membrane antigen
WO2001053353A2 (en) * 2000-01-21 2001-07-26 Novartis Ag Recombinant antibodies to human interkleukin-1 beta
WO2002002641A1 (en) * 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
WO2003034903A2 (en) * 2001-10-23 2003-05-01 Psma Development Company, L.L.C. Psma antibodies and protein multimers
WO2004020588A2 (en) * 2002-08-30 2004-03-11 Biorexis Pharmaceutical Corporation Transferrin fusion protein libraries
WO2004050850A2 (en) * 2002-12-02 2004-06-17 Abgenix, Inc. Antibodies directed to phospholipase a2 and uses thereof
US20040175385A1 (en) * 1998-08-31 2004-09-09 The Regents Of The University Of Carlifornia Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994029457A2 (en) * 1993-06-09 1994-12-22 Unilever N.V. Process for producing fusion proteins comprising scfv fragments by a transformed mould
US20040175385A1 (en) * 1998-08-31 2004-09-09 The Regents Of The University Of Carlifornia Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
WO2001009192A1 (en) * 1999-07-29 2001-02-08 Medarex, Inc. Human monoclonal antibodies to prostate specific membrane antigen
WO2001053353A2 (en) * 2000-01-21 2001-07-26 Novartis Ag Recombinant antibodies to human interkleukin-1 beta
WO2002002641A1 (en) * 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
WO2003034903A2 (en) * 2001-10-23 2003-05-01 Psma Development Company, L.L.C. Psma antibodies and protein multimers
WO2004020588A2 (en) * 2002-08-30 2004-03-11 Biorexis Pharmaceutical Corporation Transferrin fusion protein libraries
WO2004050850A2 (en) * 2002-12-02 2004-06-17 Abgenix, Inc. Antibodies directed to phospholipase a2 and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DONOVAN G P ET AL: "ANTIBODY AND VACCINE THERAPIES TARGETING PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA)", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, US, vol. 42, 24 March 2001 (2001-03-24), pages 818, XP001204629, ISSN: 0197-016X *
HOLMES E H: "PSMA specific antibodies and their diagnostic and therapeutic use", EXPERT OPINION ON INVESTIGATIONAL DRUGS, ASHLEY PUBLICATIONS LTD., LONDON, GB, vol. 10, no. 3, 2001, pages 511 - 519, XP002988381, ISSN: 1354-3784 *
LIU H ET AL: "MONOCLONAL ANTIBODIES TO THE EXTRACELLULAR DOMAIN OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN ALSO REACT WITH TUMOR VASCULAR ENDOTHELIUM", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 57, no. 17, 1 September 1997 (1997-09-01), pages 3629 - 3634, XP001080132, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
WO2003064606A3 (en) 2005-02-03
KR20040077889A (en) 2004-09-07
CA2474616A1 (en) 2003-08-07
AU2003224604B2 (en) 2007-06-14
NZ534687A (en) 2007-10-26
WO2003064606A2 (en) 2003-08-07
JP2005518789A (en) 2005-06-30
BR0307216A (en) 2005-12-20
EP1519747A2 (en) 2005-04-06
MXPA04007262A (en) 2004-10-29
CN1652821A (en) 2005-08-10

Similar Documents

Publication Publication Date Title
EP1519747A4 (en) Human monoclonal antibodies to prostate specific membrane antigen (psma)
PL1851250T3 (en) Human monoclonal antibody to prostate specific membrane antigen (psma)
HK1153649A1 (en) Therapeutic anti-il-1r1 monoclonal antibody il-1r1
IL161705A0 (en) Human monoclonal antibodies to dendritic cells
EP1633785A4 (en) Human monoclonal antibodies against bacillusanthracis protective antigen
CY2012019I1 (en) HUMAN MONOCLONAL ANTIBODIES AGAINST CD20
IL157274A0 (en) Human monoclonal antibodies to fc alpha receptor (cd89)
IL173273A0 (en) Modified human igf-1r antibodies
HK1077226A1 (en) Human monoclonal antibodies against cd25
IL179672A (en) Human monoclonal anti-cd3 antibodies
EP1471938A4 (en) Human monoclonal antibodies against cd30
IL172242A0 (en) Antibodies specific for cancer associated antigen sm5-1 and uses thereof
AU2003209059A1 (en) Human monoclonal antibodies against membrane proteins
IL180789A0 (en) Human monoclonal antibodies against human il-4
EP1646401A4 (en) Specific human antibodies
EP1556499A4 (en) Monoclonal antibodies specific for cariogenic bacteria
FI20020807A0 (en) Novel humanized anti-VAP-1 monoclonal antibodies
EP1559725A4 (en) Antigen recognizing antibody
SI1851250T1 (en) Human monoclonal antibody to prostate specific membrane antigen (psma)
EP1446416A4 (en) Tumor specific monoclonal antibodies
ZA200200730B (en) Human monoclonal antibodies to prostate specific membrane antigen.
GB0325391D0 (en) Human monoclonal antibodies
GB0017139D0 (en) Human monoclonal antibodies
GB0016824D0 (en) Human monoclonal antibodies
SI1656391T1 (en) Modified human igf-1r antibodies

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040820

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO

A4 Supplementary search report drawn up and despatched

Effective date: 20060213

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1079085

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060517

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1079085

Country of ref document: HK